Scandion Oncology Signs Contract with Solural Pharma to Formulate SCO-101 Tablets for Clinical Phase II Trial
2019-03-18 · Scandion Oncology A/S · original scandiononcology.com ↗
· Scandion Oncology A/S and Solural Pharma ApS have entered into an agreement regarding manufacturing of SCO-101 tablets for clinical phase II trials with drug-resistant cancer patients. · Scandion Oncology will soon be completing the validation and substance production of SCO-101 at Cambrex, Sweden. Next step will be to initiate production of tablets. Scandion Oncology has employed an experienced team of drug production specialists. The team has previously been involved in the original production and formulation of SCO-101 in the four completed phase I studies. · Saniona, the main shareholder in Scandion Oncology, recently performed a legally required audit of Solural Pharma. This audit is valid and usable for Scandion Oncology. · The manufacturing of SCO-101 tablets is in accordance with Scandion Oncology’s plans and targets for 2019.
The release as fetched from its publisher. scandiononcology.com ↗